The company’s shares of confidence were underlined by an upgraded 2026 outlook, with Merck now expecting annual net sales of up to €21.4 billion and EBITDA pre of as much as €6.1 billion
Highlighting KEYTRUDA & expanding cancer pipeline
Initiatives include scholarships, STEM initiatives, and healthcare capacity-building programmes supporting women and girls across 52 countries
At the center of the deal is TERN-701, a drug recently granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration for adults with Philadelphia chromosome-positive chronic myeloid leukemia
But acquisition charges drag earnings into loss
The trials -- ELOWEN-1 and ELOWEN-2 -- are designed to evaluate the drug in people living with lupus who experience active skin manifestations
The collaboration will roll out an “agentic” AI platform across Merck’s research & development, manufacturing, commercial, and corporate operations
The newly approved pill combines 100 mg of doravirine with 0.25 mg of islatravir
If approved, the move would significantly broaden the use of KEYTRUDA and KEYTRUDA QLEX in combination with Padcev
Solvents made from renewable feedstocks help reduce reliance on fossil-fuel-based materials
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
